ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

KPTI Karyopharm Therapeutics Inc

0.945
-0.075 (-7.35%)
15 Jun 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type
Karyopharm Therapeutics Inc NASDAQ:KPTI NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -0.075 -7.35% 0.945 0.9205 6.50 1.01 0.9444 0.9951 636,543 05:00:14

Form SC 13G - Statement of acquisition of beneficial ownership by individuals

23/05/2024 9:30pm

Edgar (US Regulatory)


 

 

 

United States

Securities and Exchange Commission

Washington, D.C. 20549

 

Schedule 13G

 

(Rule 13d-102)

 


Information to be Included in Statements Filed Pursuant

to § 240.13d-1(b), (c) and (d) and Amendments Thereto Filed

Pursuant to § 240.13d-2

 

UNDER THE SECURITIES EXCHANGE ACT OF 1934

 

(Amendment No. )*

 

Karyopharm Therapeutics Inc.

(Name of Issuer)

 

Common Stock

(Title of Class of Securities)

 

48576U106

(CUSIP Number)

 

May 13, 2024

(Date of Event Which Requires Filing of this Statement)

 

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

 

Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)

 

* The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

 

The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

 

 

 

 

 

 

CUSIP No. 48576U106

Schedule 13G

Page 1 of 6

 

1

Names of Reporting Persons

J. Wood Capital Advisors LLC 

2

Check the Appropriate Box if a Member of a Group

(a) ☐
(b) ☐

3

SEC Use Only

 

4

Citizenship or Place of Organization

 

California 

Number of Shares Beneficially Owned by Each Reporting Person With 5

Sole Voting Power

6

Shared Voting Power

6,872,027 

7

Sole Dispositive Power

0

8

Shared Dispositive Power

 

6,872,027

9

Aggregate Amount Beneficially Owned by Each Reporting Person

 

6,872,027

10

Check if the Aggregate Amount in Row (9) Excludes Certain Shares

 

Not Applicable

11

Percent of Class Represented by Amount in Row 9

 

5.5%

12

Type of Reporting Person

OO (Limited Liability Company)

 

 

 

 

CUSIP No. 48576U106

Schedule 13G

Page 2 of 6

 

1

Names of Reporting Persons

Jason Wood 

2

Check the Appropriate Box if a Member of a Group

(a) ☐
(b) ☐

3

SEC Use Only

 

4

Citizenship or Place of Organization

 

United States 

Number of Shares Beneficially Owned by Each Reporting Person With 5

Sole Voting Power

 


6

Shared Voting Power

 


6,872,027 

7

Sole Dispositive Power

 


0

8

Shared Dispositive Power

 

6,872,027

9

Aggregate Amount Beneficially Owned by Each Reporting Person

 

6,872,027

10

Check if the Aggregate Amount in Row (9) Excludes Certain Shares

 

Not Applicable

11

Percent of Class Represented by Amount in Row 9

 

5.5%

12 Type of Reporting Person

IN

 

 

 

 

CUSIP No. 48576U106

Schedule 13G

Page 3 of 6

 

ITEM 1.(a) Name of Issuer:
    
   Karyopharm Therapeutics Inc. (the “Issuer”)

 

(b)Address of Issuer’s Principal Executive Offices:
    
   85 Wells Avenue, 2nd Floor, Newton, MA 02459

 

ITEM 2.(a) Name of Person Filing:
    
   Each of the following is hereinafter individually referred to as a “Reporting Person” and collectively as the “Reporting Persons.” This statement is filed on behalf of:
    
   J. Wood Capital Advisors LLC
   Jason Wood
    
 (b) Address or Principal Business Office:
    
   The principal business address of each of the Reporting Persons is 1820 Calistoga Road, Santa Rosa, CA 95404.
    
 (c) Citizenship of each Reporting Person is:
    
   J. Wood Capital Advisors LLC is organized under the laws of the state of California. Jason Wood is a citizen of the United States.
    
 (d) Title of Class of Securities:
    
   Common stock, $0.0001 par value (“Common Stock”)
    
 (e) CUSIP Number:
    
   48576U106

 

ITEM 3.  

 

  Not applicable.

 

 

 

 

CUSIP No. 48576U106

Schedule 13G

Page 4 of 6

 

ITEM 4. Ownership.

 

  (a-c)

 

The ownership information presented below represents beneficial ownership of the shares of Common Stock, based upon 124,608,532 shares of Common Stock outstanding as of May 13, 2024.

 

Reporting Person 

Amount

beneficially

owned

  

Percent

of class:

   Sole power to vote or to direct the vote:   Shared power to vote or to direct the vote:  

Sole power to dispose or to direct the disposition

of:

  

Shared

power to

dispose or

to direct

the

disposition

of:

 
J. Wood Capital Advisors LLC   6,872,027    5.5%    0    6,872,027    0    6,872,027 
Jason Wood   6,872,027    5.5%    0    6,872,027    0    6,872,027 

 

J. Wood Capital Advisors LLC is the record holder of the shares of Common Stock reported herein. Jason Wood is the managing member of J. Wood Capital Advisors LLC. As a result, Jason Wood may be deemed to share beneficial ownership of the shares of Common Stock directly held by J. Wood Capital Advisors LLC.

 

ITEM 5.Ownership of Five Percent or Less of a Class.

 

Not applicable.

 

ITEM 6.Ownership of More than Five Percent on Behalf of Another Person.

 

Not applicable.

 

ITEM 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company.

 

Not applicable.

 

ITEM 8.Identification and Classification of Members of the Group.

 

Not applicable.

 

ITEM 9.Notice of Dissolution of Group.

 

Not applicable.

 

ITEM 10.Certification.

 

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §240.14a-11.

 

 

 

 

CUSIP No. 48576U106

Schedule 13G

Page 5 of 6

 

SIGNATURE

 

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

 

Date: May 23, 2024

J. Wood Capital Advisors LLC

   
  By: /s/ Jason Wood
  Name: Jason Wood
  Title: Managing Member
     
  Jason Wood
   
  /s/ Jason Wood

 

 

 

 

CUSIP No. 48576U106

Schedule 13G

Page 6 of 6

 

LIST OF EXHIBITS

 

Exhibit No.   Description
99   Joint Filing Agreement.

 

 

 

 

Exhibit 99

 

JOINT FILING AGREEMENT

 

In accordance with Rule 13d-1(k)(1) promulgated under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree that they are jointly filing this statement on Schedule 13G. Each of them is responsible for the timely filing of such statement and any amendments thereto, and for the completeness and accuracy of the information concerning such person contained therein; but none of them is responsible for the completeness or accuracy of the information concerning the other persons making the filing, unless such person knows or has reason to believe that such information is inaccurate.

 

IN WITNESS WHEREOF, the undersigned hereby execute this Joint Filing Agreement as of the 23rd day of May, 2024.

 

J. Wood Capital Advisors LLC

   
  By: /s/ Jason Wood
  Name: Jason Wood
  Title: Managing Member
     
  Jason Wood
   
  /s/ Jason Wood

 

 

 


1 Year Karyopharm Therapeutics Chart

1 Year Karyopharm Therapeutics Chart

1 Month Karyopharm Therapeutics Chart

1 Month Karyopharm Therapeutics Chart

Your Recent History